×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. I consent to receive medical updates and communications from eMediNexus, it's parent company IJCP and its industry partners.

LAICON 2022: International - Evidence for Intensive LDL-C-lowering for the Acute Coronary Syndrome

  834 Views

Dr Raman Puri, New Delhi    25 September 2022

  • During the first-month post-ACS, the risk of cardiovascular (CV) events is the highest.
  • Trials of high-intensity statins have shown a reduction in MACE in the acute, early and late phases of ACS.
  • The level of LDL-C is directly linked to the amount of plaque stabilization and the number of CV events.
  • High-intensity statins with ezetimibe should be started at emergency triage.
  • An extended lipid profile should be measured in emergency triage and repeated at weeks 2 and 4.
  • Identify the ASCVD risk category and LDL-C target per the LAI recommendation.
  • Plan a combination of lipid-lowering medications to achieve the LDL-C target.
  • All ASCVD risk factors should be controlled, and lifestyle interventions implemented.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.